Cargando…

The balance between Foxp3 and Ror-γt expression in peripheral blood is altered by tocilizumab and abatacept in patients with rheumatoid arthritis

BACKGROUND: The balance between Th17 cells and regulatory T (Treg) cells has been shown to play an important role in the development of rheumatoid arthritis (RA). Recent studies have shown that treatment with abatacept (ABT) or tocilizumab (TCZ) affects Th17 and Treg cell populations. Although not u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tada, Yoshifumi, Ono, Nobuyuki, Suematsu, Rie, Tashiro, Satoko, Sadanaga, Yuri, Tokuda, Yukiko, Ono, Yukihide, Nakao, Yoshinobu, Maruyama, Akihito, Ohta, Akihide, Koarada, Syuichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947268/ https://www.ncbi.nlm.nih.gov/pubmed/27421886 http://dx.doi.org/10.1186/s12891-016-1137-1

Ejemplares similares

Effectiveness of Certolizumab Pegol in Treating Rheumatoid Arthritis Patients with Persistent Inflamed Residual Mono- or Oligosynovitis Resistant to Prior TNF-α Inhibitors
por: Koarada, Syuichi, et al.
Publicado: (2015)

Phenotyping of P105-Negative B Cell Subsets in Patients with Systemic Lupus Erythematosus
por: Koarada, Syuichi, et al.
Publicado: (2012)

Immediate Effect of Baricitinib on Arthritis and Biological Disease-Modifying Antirheumatic Drug-Induced Psoriasis-Like Skin Lesions in Two Patients with Rheumatoid Arthritis
por: Tada, Yoshifumi, et al.
Publicado: (2021)

Toll-like receptor homolog RP105 modulates the antigen-presenting cell function and regulates the development of collagen-induced arthritis
por: Tada, Yoshifumi, et al.
Publicado: (2008)

RP105-Negative B Cells in Systemic Lupus Erythematosus
por: Koarada, Syuichi, et al.
Publicado: (2012)

Increased RP105-Negative B Cells in IgG4-Related Disease
por: Koarada, S, et al.
Publicado: (2013)

Comparing the effectiveness and safety of Abatacept and Tocilizumab in elderly patients with rheumatoid arthritis
por: Temmoku, Jumpei, et al.
Publicado: (2022)

Tocilizumab and Abatacept for the Treatment of Childhood Chronic Uveitis: A Monocentric Comparison Experience
por: Maccora, Ilaria, et al.
Publicado: (2022)

Tocilizumab Attenuates Anti-neutrophil Cytoplasmic Antibody-associated Nephritis Occurring during Abatacept and Adalimumab Therapy for Rheumatoid Arthritis
por: Yoshimura, Yusuke, et al.
Publicado: (2022)

Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates
por: Diep, Laetitia, et al.
Publicado: (2022)

Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis
por: Crnkic Kapetanovic, Meliha, et al.
Publicado: (2013)

Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity
por: Takahashi, Nobunori, et al.
Publicado: (2013)

Abatacept and tocilizumab tapering in rheumatoid arthritis patients: results of SONATA—a retrospective, exploratory cohort study
por: Bouman, Chantal A M, et al.
Publicado: (2018)

Retinoic Acid Induces Functionally Suppressive Foxp3(+)RORγt(+) T Cells In Vitro
por: Martínez-Blanco, Mónica, et al.
Publicado: (2021)

Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry
por: Harrold, Leslie R., et al.
Publicado: (2016)

Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis
por: Huoponen, Saara, et al.
Publicado: (2019)

Transcriptomic profile comparison of monocytes from rheumatoid arthritis patients in treatment with methotrexate, anti-TNFa, abatacept or tocilizumab
por: Talmon, Maria, et al.
Publicado: (2023)

Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies
por: Hirabara, Shinya, et al.
Publicado: (2014)

Effects of denosumab on bone metabolism and bone mineral density with anti-TNF inhibitors, tocilizumab, or abatacept in osteoporosis with rheumatoid arthritis
por: Suzuki, Takako, et al.
Publicado: (2018)

Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study
por: Gottenberg, Jacques-Eric, et al.
Publicado: (2019)

In vivo equilibrium of proinflammatory IL-17(+) and regulatory IL-10(+) Foxp3(+) RORγt(+) T cells
por: Lochner, Matthias, et al.
Publicado: (2008)

IL-15-dependent balance between Foxp3 and RORγt expression impacts inflammatory bowel disease
por: Tosiek, Milena J., et al.
Publicado: (2016)

Vitamin D Regulates the Microbiota to Control the Numbers of RORγt/FoxP3+ Regulatory T Cells in the Colon
por: Cantorna, Margherita T., et al.
Publicado: (2019)

Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs
por: Takeuchi, Tsutomu, et al.
Publicado: (2014)

Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: Addressing treatment outside the current NICE guidance
por: Chiu, Yee, et al.
Publicado: (2012)

Blimp-1 Functions as a Molecular Switch to Prevent Inflammatory Activity in Foxp3(+)RORγt(+) Regulatory T Cells
por: Ogawa, Chihiro, et al.
Publicado: (2018)

Abatacept in the treatment of rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2008)

Abatacept in the treatment of rheumatoid arthritis
por: Vital, Edward M, et al.
Publicado: (2006)

Abatacept treatment for rheumatoid arthritis
por: Schiff, Michael
Publicado: (2011)

Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study
por: Curtis, Jeffrey R., et al.
Publicado: (2015)

Long term treatment with abatacept or tocilizumab does not increase Epstein-Barr virus load in patients with rheumatoid arthritis - A three years retrospective study
por: Balandraud, Nathalie, et al.
Publicado: (2017)

Digoxin, an Overlooked Agonist of RORγ/RORγT
por: Karaś, Kaja, et al.
Publicado: (2019)

ROR1 and ROR2 expression in pancreatic cancer
por: Liu, Dongli, et al.
Publicado: (2021)

Elevated IL-23R Expression and Foxp3(+)Rorγt(+) Cells in Intestinal Mucosa During Acute and Chronic Colitis
por: Yang, Jiayin, et al.
Publicado: (2016)

Genetic variation in FOXP3 and ROR-γ genes in pediatric acute lymphocytic leukemia (ALL) patients: correlation with associated cytokines
por: El-maadawy, Eman A., et al.
Publicado: (2022)

From stability to dynamics: understanding molecular mechanisms of regulatory T cells through Foxp3 transcriptional dynamics
por: Bending, D., et al.
Publicado: (2018)

Role of Dust and Iron Solubility in Sulfate Formation during the Long-Range Transport in East Asia Evidenced by (17)O-Excess Signatures
por: Itahashi, Syuichi, et al.
Publicado: (2022)

Mean cost per number needed to treat with tocilizumab plus methotrexate versus abatacept plus methotrexate in the treatment of rheumatoid arthritis in patients previously treated with methotrexate
por: Benucci, Maurizio, et al.
Publicado: (2017)

Increased T-bet/GATA-3 and ROR-γt /Foxp3 Ratios in Cerebrospinal Fluid as Potential Criteria for Definite Neuro-Behçet’s Disease
por: Belghith, Meriam, et al.
Publicado: (2022)

Subcutaneous abatacept for the treatment of rheumatoid arthritis
por: Schiff, Michael
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_32s17jp51p4su7rufgc2e8iof8